Current situation and prospect of interventional therapy for congenital heart disease in China_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

YAN Yiming ^1,2,3,4 , OUYANG Wenbin ^1,2,3,4 , ZHANG Fengwen ^1,2,3,4 , FANG Fang ^1,2,3,4 ,  PAN Xiangbin ^1,2,3,4

1. Department of Structural Heart Disease, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100037, P. R. China;
2. National Health Commission Key Laboratory of Cardiovascular Regeneration Medicine, Beijing, 100037, P. R. China;
3. Key Laboratory of Innovative Cardiovascular Devices, Chinese Academy of Medical Sciences, Beijing, 100037, P. R. China;
4. National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, 100037, P. R. China;

Corresponding?author：

PAN Xiangbin, Email: panxiangbin@fuwaihospital.org

Keywords：

Congenital heart disease; interventional therapy; occluder device; commentary

DOI：

10.7507/1007-4848.202205081

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Transcatheter intervention for congenital heart disease has been developed for 40 years in China, it has experienced the transition of learning to self-dependent innovation, and witnessed the intervention therapy system starting from scratch and gradually reaching the top level and gaining high achievements in the world scale. With the continuous development of interventional technology and devices, cutting-edge ideas and viewpoints are constantly discussed. This review summarized the development of intervention techniques and devices, hoping to provide some experience for the further development of transcatheter interventions for congenial heart disease.

Citation： YAN Yiming, OUYANG Wenbin, ZHANG Fengwen, FANG Fang, PAN Xiangbin. Current situation and prospect of interventional therapy for congenital heart disease in China. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2022, 29(10): 1243-1253. doi: 10.7507/1007-4848.202205081 Copy

1.	van der Linde D, Konings EE, Slager MA, et al. Birth prevalence of congenital heart disease worldwide: A systematic review and meta-analysis. J Am Coll Cardiol, 2011, 58(21): 2241-2247.
2.	Zhao L, Chen L, Yang T, et al. Birth prevalence of congenital heart disease in China, 1980-2019: A systematic review and meta-analysis of 617 studies. Eur J Epidemiol, 2020, 35(7): 631-642.
3.	國家心血管病中心. 中國心血管病報告 2018. 北京: 中國大百科全書出版社, 2019. 1-100.
4.	潘湘斌. 超聲引導經皮介入治療結構性心臟病的探索和發展前景. 中國胸心血管外科臨床雜志, 2018, 25(5): 359-361.
5.	國家心血管病醫療質量控制中心. 《2021年中國心血管病醫療質量報告》概要. 中國循環雜志, 2021, 36(11): 1041-1064.
6.	Forssmann W. Die sondierung des rechten herzens. Klinische Wochenschrift, 1929, 8(45): 2085-2087.
7.	Raju TN. The Nobel chronicles1956: Werner Forssmann (1904-79); André Frédéric Cournand (1895-1988); and Dickinson Woodruff Richards, Jr (1895-1973). Lancet, 1999, 353(9167): 1891.
8.	Bougas J, Goldberg H, Musser BG. Left heart catheterization. Ⅰ. Clinical methods and applications. Am Heart J, 1956, 52(3): 359-368.
9.	Rashkind WJ. Creation of an atrial septal defect without thoracotomy. A palliative approach to complete transposition of the great arteries. JAMA, 1966, 196(11): 991-992.
10.	周愛卿, 王榮發, 高偉, 等. 復雜性先天性心臟病的介入治療. 中華兒科雜志, 2004, 42(11): 813-816.
11.	Porstmann W, Wierny L. Percutaneous transfemoral closure of the patent ductus arteriosus—An alternative to surgery. Semin Roentgenol, 1981, 16(2): 95-102.
12.	錢晉卿, 謝亞藩, 沈維英, 等. 非開胸法關閉動脈導管130例報告. 中華心血管病雜志, 1992, 20(3): 167-168.
13.	錢梓靜, 王舒, 錢晉卿, 等. 動脈導管未閉堵塞術18例報告. 中華放射學雜志, 1987, 21(5): 282-285.
14.	King TD, Thompson SL, Steiner C, et al. Secundum atrial septal defect. Nonoperative closure during cardiac catheterization. JAMA, 1976, 235(23): 2506-2509.
15.	Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC guidelines for the management of adult congenital heart disease. Eur Heart J, 2021, 42(6): 563-645.
16.	Vaidyanathan B, Simpson JM, Kumar RK. Transesophageal echocardiography for device closure of atrial septal defects. JACC Cardiovasc Imaging, 2009, 2(10): 1238-1242.
17.	Marie Valente A, Rhodes JF. Current indications and contraindications for transcatheter atrial septal defect and patent foramen ovale device closure. Am Heart J, 2007, 153(4 Suppl): 81-84.
18.	Kan JS, White RI, Mitchell SE, et al. Percutaneous balloon valvuloplasty: A new method for treating congenital pulmonary-valve stenosis. N Engl J Med, 1982, 307(9): 540-542.
19.	毛繼文, 王錦志, 齊向前, 等. 經皮球囊導管肺動脈瓣成形術血液動力學的初步結果. 臨床心血管病雜志, 1987, 3(2): 66-68.
20.	Reidy JF, Sowton E, Ross DN. Transcatheter occlusion of coronary to bronchial anastomosis by detachable balloon combined with coronary angioplasty at same procedure. Br Heart J, 1983, 49(3): 284-287.
21.	Lock JE, Block PC, McKay RG, et al. Transcatheter closure of ventricular septal defects. Circulation, 1988, 78(2): 361-368.
22.	秦永文, 丁仲如. 室間隔缺損的介入治療及評價. 中國醫師進修雜志, 2007, 30(1): 8-10.
23.	Yang J, Yang L, Yu S, et al. Transcatheter versus surgical closure of perimembranous ventricular septal defects in children: A randomized controlled trial. J Am Coll Cardiol, 2014, 63(12): 1159-1168.
24.	Santhanam H, Yang L, Chen Z, et al. A meta-analysis of transcatheter device closure of perimembranous ventricular septal defect. Int J Cardiol, 2018, 254: 75-83.
25.	Weryński P, Skorek P, Wójcik A, et al. Recent achievements in transcatheter closure of ventricular septal defects: A systematic review of literature and a meta-analysis. Kardiol Pol, 2021, 79(2): 161-169.
26.	Bridges ND, Hellenbrand W, Latson L, et al. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation, 1992, 86(6): 1902-1908.
27.	Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med, 2012, 366(11): 991-999.
28.	Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med, 2013, 368(12): 1092-1100.
29.	Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med, 2013, 368(12): 1083-1091.
30.	S?ndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med, 2017, 377(11): 1033-1042.
31.	Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med, 2017, 377(11): 1011-1021.
32.	Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med, 2017, 377(11): 1022-1032.
33.	中國心血管健康與疾病報告2019. 心肺血管病雜志, 2020, 39(10): 1157-1162.
34.	國家衛生健康委員會國家結構性心臟病介入質量控制中心,國家心血管病中心結構性心臟病介入質量控制中心,中華醫學會心血管病學分會先心病經皮介入治療指南工作組,等. 常見先天性心臟病經皮介入治療指南(2021版). 中華醫學雜志, 2021, 101(38): 3054-3076.
35.	Sharafuddin MJ, Gu X, Titus JL, et al. Experimental evaluation of a new self-expanding patent ductus arteriosus occluder in a canine model. J Vasc Interv Radiol, 1996, 7(6): 877-887.
36.	Sharafuddin MJ A, Gu X, Titus JL, et al. Transvenous closure of secundum atrial septal defects: Preliminary results with a new self-expanding nitinol prosthesis in a swine model. Circulation, 1997, 95(8): 2162-2168.
37.	Thanopoulos BD, Laskari CV, Tsaousis GS, et al. Closure of atrial septal defects with the Amplatzer occlusion device: Preliminary results. J Am Coll Cardiol, 1998, 31(5): 1110-1116.
38.	Thanopoulos BD, Tsaousis GS, Konstadopoulou GN, et al. Transcatheter closure of muscular ventricular septal defects with the amplatzer ventricular septal defect occluder: Initial clinical applications in children. J Am Coll Cardiol, 1999, 33(5): 1395-1399.
39.	戴汝平, 劉延玲, 張戈軍,等. 應用Amplatzer封堵器介入治療房間隔缺損療效評價(附60例報告). 中華心血管病雜志, 2000, 28(2): 87.
40.	蔣世良. 中國先天性心臟病介入治療現狀. 中國實用內科雜志, 2013, 33(4): 259-262.
41.	龐程程, 潘微, 張智偉, 等. 室間隔完整的嚴重肺動脈瓣狹窄或閉鎖胎兒心臟介入治療二例. 中華兒科雜志, 2018, 56(6): 445-450.
42.	張戈軍, 戴汝平, 劉延玲, 等. 房間隔缺損直徑的各種測量方法在介入治療中應用價值. 中國介入心臟病學雜志, 2000, 8(4): 19-22.
43.	Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol, 2004, 44(9): 1780-1785.
44.	Hellenbrand WE, Fahey JT, McGowan FX, et al. Transesophageal echocardiographic guidance of transcatheter closure of atrial septal defect. Am J Cardiol, 1990, 66(2): 207-213.
45.	Kardon RE, Sokoloski MC, Levi DS, et al. Transthoracic echocardiographic guidance of transcatheter atrial septal defect closure. Am J Cardiol, 2004, 94(2): 256-260.
46.	潘湘斌, 逄坤靜, 胡盛壽, 等. 經食管超聲心動圖引導下介入治療房間隔缺損幼兒的有效性和安全性. 中華心血管病雜志, 2013, 41(9): 744-746.
47.	潘湘斌, 逄坤靜, 歐陽文斌, 等. 單純超聲心動圖引導下經皮室間隔缺損封堵術的應用研究. 中國循環雜志, 2015, 30(8): 774-776.
48.	潘湘斌, 歐陽文斌, 李守軍, 等. 單純超聲心動圖引導下行動脈導管未閉封堵術的安全性和有效性. 中華心血管病雜志, 2015, 43(1): 31-33.
49.	Yang T, Butera G, Ou-Yang WB, et al. Percutaneous closure of patent foramen ovale under transthoracic echocardiography guidance-midterm results. J Thorac Dis, 2019, 11(6): 2297-2304.
50.	潘湘斌, 胡盛壽, 歐陽文斌, 等. 單純超聲引導下經皮肺動脈瓣球囊成形術的應用研究. 中華小兒外科雜志, 2015, 36(4): 286-288.
51.	Kong P, Zhao G, Zhang Z, et al. Novel panna guide wire facilitates percutaneous and nonfluoroscopic procedure for atrial septal defect closure: A randomized controlled trial. Circ Cardiovasc Interv, 2020, 13(9): e009281.
52.	Liu Y, Guo GL, Zhang FW, et al. A novel wire is effective for echo-guiding percutaneous atrial septal defect closure: A preclinical study. J Healthc Eng, 2018, 2018: 5784567.
53.	Ovaert C, Bonnet D, Malekzadeh-Milani S. Letter by Ovaert et al regarding article, "Novel panna guide wire facilitates percutaneous and nonfluoroscopic procedure for atrial septal defect closure: A randomized controlled trial". Circ Cardiovasc Interv, 2020, 13(11): e010121.
54.	Wang C, Zhang F, Ouyang W, et al. Transcatheter closure of patent ductus arteriosus under echocardiography guidance: A randomized controlled noninferiority trial. J Interv Cardiol, 2020, 2020: 4357017.
55.	國家衛生健康委員會國家心外介入質控專家組, 國家心血管病中心醫療質量控制中心心外介入專家組. 單純超聲心動圖引導經皮介入技術中國專家共識. 中國循環雜志, 2018, 33(10): 943-952.
56.	Antoniades C, Asselbergs FW, Vardas P. The year in cardiovascular medicine 2020: Digital health and innovation. Eur Heart J, 2021, 42(7): 732-739.
57.	Arnaout R, Curran L, Zhao Y, et al. An ensemble of neural networks provides expert-level prenatal detection of complex congenital heart disease. Nat Med, 2021, 27(5): 882-891.
58.	Morris SA, Lopez KN. Deep learning for detecting congenital heart disease in the fetus. Nat Med, 2021, 27(5): 764-765.
59.	李林林, 于振坤, 樊紅光, 等. 虛擬現實技術在心血管外科手術教學培訓中的初步應用研究. 中國循環雜志, 2019, 34(3): 289-294.
60.	Vukicevic M, Mosadegh B, Min JK, et al. Cardiac 3D printing and its future directions. JACC Cardiovasc Imaging, 2017, 10(2): 171-184.
61.	Sigler M, Jux C. Biocompatibility of septal defect closure devices. Heart, 2007, 93(4): 444-449.
62.	Huang Y, Kong JF, Venkatraman SS. Biomaterials and design in occlusion devices for cardiac defects: A review. Acta Biomater, 2014, 10(3): 1088-1101.
63.	Zahn EM, Wilson N, Cutright W, et al. Development and testing of the Helex septal occluder, a new expanded polytetrafluoroethylene atrial septal defect occlusion system. Circulation, 2001, 104(6): 711-716.
64.	Lin C, Liu L, Liu Y, et al. Recent developments in next-generation occlusion devices. Acta Biomater, 2021, 128: 100-119.
65.	Kaulitz R, Bertram H, Peuster M, et al. Transcatheter closure of atrial septal defects with the CardioSEAL occluder. Z Kardiol, 2002, 91(2): 169-177.
66.	Nugent AW, Britt A, Gauvreau K, et al. Device closure rates of simple atrial septal defects optimized by the STARFlex device. J Am Coll Cardiol, 2006, 48(3): 538-544.
67.	Rao PS, Sideris EB, Haddad J, et al. Transcatheter occlusion of patent ductus arteriosus with adjustable buttoned device. Initial clinical experience. Circulation, 1993, 88(3): 1119-1126.
68.	Majunke N, Sievert H. ASD/PFO devices: what is in the pipeline? J Interv Cardiol, 2007, 20(6): 517-523.
69.	Gruenstein DH, Ebeid M, Radtke W, et al. Transcatheter closure of patent ductus arteriosus using the AMPLATZER? duct occluder Ⅱ (ADO Ⅱ). Catheter Cardiovasc Interv, 2017, 89(6): 1118-1128.
70.	Numan M, El Sisi A, Tofeig M, et al. Cribriform amplatzer device closure of fenestrated atrial septal defects: Feasibility and technical aspects. Pediatr Cardiol, 2008, 29(3): 530-535.
71.	Koneti NR, Penumatsa RR, Kanchi V, et al. Retrograde transcatheter closure of ventricular septal defects in children using the Amplatzer Duct Occluder Ⅱ. Catheterization and Cardiovascular Interventions, 2011, 77(2): 252-259.
72.	Koneti NR, Penumatsa RR, Kanchi V, et al. Retrograde transcatheter closure of ventricular septal defects in children using the Amplatzer Duct Occluder Ⅱ. Catheter Cardiovasc Interv, 2011, 77(2): 252-259.
73.	張戈軍, 徐仲英, 蔣世良, 等. 第二代Amplatzer動脈導管未閉封堵器經股動脈逆行插管行室間隔缺損封堵術療效評價. 臨床薈萃, 2015, 30(6): 601-604.
74.	Haddad RN, Daou L, Saliba Z. Device closure of perimembranous ventricular septal defect: Choosing between amplatzer occluders. Front Pediatr, 2019, 7: 300.
75.	Holzer R, de Giovanni J, Walsh KP, et al. Transcatheter closure of perimembranous ventricular septal defects using the amplatzer membranous VSD occluder: Immediate and midterm results of an international registry. Catheter Cardiovasc Interv, 2006, 68(4): 620-628.
76.	Butera G, Carminati M, Chessa M, et al. Transcatheter closure of perimembranous ventricular septal defects: Early and long-term results. J Am Coll Cardiol, 2007, 50(12): 1189-1195.
77.	Zuo J, Xie J, Yi W, et al. Results of transcatheter closure of perimembranous ventricular septal defect. Am J Cardiol, 2010, 106(7): 1034-1037.
78.	Yang J, Yang L, Wan Y, et al. Transcatheter device closure of perimembranous ventricular septal defects: Mid-term outcomes. Eur Heart J, 2010, 31(18): 2238-2245.
79.	李俊杰, 張智偉, 錢明陽, 等. 應用偏心型和對稱型封堵器介入治療小兒膜周部室間隔缺損的對比研究. 中國介入心臟病學雜志, 2009, 17(6): 301-304.
80.	秦永文, 趙仙先, 徐榮良, 等. 應用自制封堵器經導管閉合膜部室間隔缺損. 中華心血管病雜志, 2003, 31(1): 31.
81.	袁建華. 淺談介入治療技術的規范化. 介入放射學雜志, 2005, 14(4): 427-429.
82.	秦永文, 趙仙先, 吳弘, 等. 自制非對稱型室間隔缺損封堵器的初步臨床應用. 介入放射學雜志, 2004, 13(2): 101-103.
83.	Ou-Yang WB, Li SJ, Wang SZ, et al. Echocardiographic guided closure of perimembranous ventricular septal defects. Ann Thorac Surg, 2015, 100(4): 1398-1402.
84.	Yang K, Lyu JH, Hu HB, et al. Efficacy and safety of a parylene-coated occluder for atrial septal defect: A prospective, multi-center, randomized controlled clinical trial. Chin Med J (Engl), 2021, 134(22): 2685-2691.
85.	Esteves CA, Solarewicz LA, Cassar R, et al. Occlusion of the perimembranous ventricular septal defect using CERA? devices. Catheter Cardiovasc Interv, 2012, 80(2): 182-187.
86.	Lifeng Z, Yan H, Dayun Y, et al. The underlying biological mechanisms of biocompatibility differences between bare and TiN-coated NiTi alloys. Biomed Mater, 2011, 6(2): 025012.
87.	Kaya MG, Akpek M, Celebi A, et al. A multicentre, comparative study of Cera septal occluder versus AMPLATZER Septal Occluder in transcatheter closure of secundum atrial septal defects. EuroIntervention, 2014, 10(5): 626-631.
88.	Ulmi M, Praz F, Siontis GCM, et al. Propensity-score matched comparison of the cera PFO occluder with the Amplatzer PFO occluder for percutaneous closure of patent foramen ovale without echocardiographic guidance. J Invasive Cardiol, 2017, 29(8): 280-284.
89.	Bhattacharjya S, Pillai LS, Doraiswamy V, et al. Prospective concurrent head-to head comparison of three different types of nitinol occluder device for transcatheter closure of secundum atrial septal defects. EuroIntervention, 2019, 15(4): e321-e328.
90.	Sievert K, Yu J, Bertog S, et al. Post-market clinical follow-up with the patent foramen ovale closure device IrisFIT (Lifetech) in patients with stroke, transient ischemic attack, or other thromboembolic events. Cardiovasc Revasc Med, 2021, 30: 72-75.
91.	Ramot Y, Haim-Zada M, Domb AJ, et al. Biocompatibility and safety of PLA and its copolymers. Adv Drug Deliv Rev, 2016, 107: 153-162.
92.	da Silva D, Kaduri M, Poley M, et al. Biocompatibility, biodegradation and excretion of polylactic acid (PLA) in medical implants and theranostic systems. Chem Eng J, 2018, 340: 9-14.
93.	In vitro degradation behavior of l-lactide/trimethylene carbonate/glycolide terpolymers and a composite with poly (l-lactide-co-glycolide) fibers-ScienceDirect. [2022-05-07]. https://www.sciencedirect.com/science/article/pii/S0141391014004297.
94.	Middleton JC, Tipton AJ. Synthetic biodegradable polymers as orthopedic devices. Biomaterials, 2000, 21(23): 2335-2346.
95.	Goonoo N, Jeetah R, Bhaw-Luximon A, et al. Polydioxanone-based bio-materials for tissue engineering and drug/gene delivery applications. Eur J Pharm Biopharm, 2015, 97(Pt B): 371-391.
96.	Bartnikowski M, Dargaville T R, Ivanovski S, et al. Degradation mechanisms of polycaprolactone in the context of chemistry, geometry and environment. Progress in Polymer Science, 2019, 96: 1-20.
97.	Jux C, Bertram H, Wohlsein P, et al. Interventional atrial septal defect closure using a totally bioresorbable occluder matrix: Development and preclinical evaluation of the BioSTAR device. J Am Coll Cardiol, 2006, 48(1): 161-169.
98.	Mullen MJ, Devellian CA, Jux C. BioSTAR bioabsorbable septal repair implant. Expert Rev Med Devices, 2007, 4(6): 781-792.
99.	Mullen MJ, Hildick-Smith D, De Giovanni JV, et al. BioSTAR Evaluation STudy (BEST): A prospective, multicenter, phaseⅠclinical trial to evaluate the feasibility, efficacy, and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial-level shunts. Circulation, 2006, 114(18): 1962-1967.
100.	Morgan G, Lee KJ, Chaturvedi R, et al. A biodegradable device (BioSTAR) for atrial septal defect closure in children. Catheter Cardiovasc Interv, 2010, 76(2): 241-245.
101.	Baspinar O, Kervancioglu M, Kilinc M, et al. Bioabsorbable atrial septal occluder for percutaneous closure of atrial septal defect in children. Tex Heart Inst J, 2012, 39(2): 184-189.
102.	Sigler M, S?derberg B, Schmitt B, et al. Carag bioresorbable septal occluder (CBSO): Histopathology of experimental implants. EuroIntervention, 2018, 13(14): 1655-1661.
103.	Liu SJ, Peng KM, Hsiao CY, et al. Novel biodegradable polycaprolactone occlusion device combining nanofibrous PLGA/collagen membrane for closure of atrial septal defect (ASD). Ann Biomed Eng, 2011, 39(11): 2759-2766.
104.	Zhu YF, Huang XM, Cao J, et al. Animal experimental study of the fully biodegradable atrial septal defect (ASD) occluder. J Biomed Biotechnol, 2012, 2012: 735989.
105.	Huang XM, Zhu YF, Cao J, et al. Development and preclinical evaluation of a biodegradable ventricular septal defect occluder. Catheter Cardiovasc Interv, 2013, 81(2): 324-330.
106.	Li YF, Xie YM, Chen J, et al. Initial experiences with a novel biodegradable device for percutaneous closure of atrial septal defects: From preclinical study to first-in-human experience. Catheter Cardiovasc Interv, 2020, 95(2): 282-293.
107.	Lin C, Lv J, Li Y, et al. 4D-printed biodegradable and remotely controllable shape memory occlusion devices. Adv Funct Mater, 2019, 29(51): 1906569.
108.	Lu W, Ouyang W, Wang S, et al. A novel totally biodegradable device for effective atrial septal defect closure: A 2-year study in sheep. J Interv Cardiol, 2018, 31(6): 841-848.
109.	張鳳文, 孫毅, 潘湘斌, 等. 完全可降解封堵器治療膜周部室間隔缺損兩例. 中國胸心血管外科臨床雜志, 2018, 25(7): 636-638.

1. van der Linde D, Konings EE, Slager MA, et al. Birth prevalence of congenital heart disease worldwide: A systematic review and meta-analysis. J Am Coll Cardiol, 2011, 58(21): 2241-2247.
2. Zhao L, Chen L, Yang T, et al. Birth prevalence of congenital heart disease in China, 1980-2019: A systematic review and meta-analysis of 617 studies. Eur J Epidemiol, 2020, 35(7): 631-642.
3. 國家心血管病中心. 中國心血管病報告 2018. 北京: 中國大百科全書出版社, 2019. 1-100.
4. 潘湘斌. 超聲引導經皮介入治療結構性心臟病的探索和發展前景. 中國胸心血管外科臨床雜志, 2018, 25(5): 359-361.
5. 國家心血管病醫療質量控制中心. 《2021年中國心血管病醫療質量報告》概要. 中國循環雜志, 2021, 36(11): 1041-1064.
6. Forssmann W. Die sondierung des rechten herzens. Klinische Wochenschrift, 1929, 8(45): 2085-2087.
7. Raju TN. The Nobel chronicles1956: Werner Forssmann (1904-79); André Frédéric Cournand (1895-1988); and Dickinson Woodruff Richards, Jr (1895-1973). Lancet, 1999, 353(9167): 1891.
8. Bougas J, Goldberg H, Musser BG. Left heart catheterization. Ⅰ. Clinical methods and applications. Am Heart J, 1956, 52(3): 359-368.
9. Rashkind WJ. Creation of an atrial septal defect without thoracotomy. A palliative approach to complete transposition of the great arteries. JAMA, 1966, 196(11): 991-992.
10. 周愛卿, 王榮發, 高偉, 等. 復雜性先天性心臟病的介入治療. 中華兒科雜志, 2004, 42(11): 813-816.
11. Porstmann W, Wierny L. Percutaneous transfemoral closure of the patent ductus arteriosus—An alternative to surgery. Semin Roentgenol, 1981, 16(2): 95-102.
12. 錢晉卿, 謝亞藩, 沈維英, 等. 非開胸法關閉動脈導管130例報告. 中華心血管病雜志, 1992, 20(3): 167-168.
13. 錢梓靜, 王舒, 錢晉卿, 等. 動脈導管未閉堵塞術18例報告. 中華放射學雜志, 1987, 21(5): 282-285.
14. King TD, Thompson SL, Steiner C, et al. Secundum atrial septal defect. Nonoperative closure during cardiac catheterization. JAMA, 1976, 235(23): 2506-2509.
15. Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC guidelines for the management of adult congenital heart disease. Eur Heart J, 2021, 42(6): 563-645.
16. Vaidyanathan B, Simpson JM, Kumar RK. Transesophageal echocardiography for device closure of atrial septal defects. JACC Cardiovasc Imaging, 2009, 2(10): 1238-1242.
17. Marie Valente A, Rhodes JF. Current indications and contraindications for transcatheter atrial septal defect and patent foramen ovale device closure. Am Heart J, 2007, 153(4 Suppl): 81-84.
18. Kan JS, White RI, Mitchell SE, et al. Percutaneous balloon valvuloplasty: A new method for treating congenital pulmonary-valve stenosis. N Engl J Med, 1982, 307(9): 540-542.
19. 毛繼文, 王錦志, 齊向前, 等. 經皮球囊導管肺動脈瓣成形術血液動力學的初步結果. 臨床心血管病雜志, 1987, 3(2): 66-68.
20. Reidy JF, Sowton E, Ross DN. Transcatheter occlusion of coronary to bronchial anastomosis by detachable balloon combined with coronary angioplasty at same procedure. Br Heart J, 1983, 49(3): 284-287.
21. Lock JE, Block PC, McKay RG, et al. Transcatheter closure of ventricular septal defects. Circulation, 1988, 78(2): 361-368.
22. 秦永文, 丁仲如. 室間隔缺損的介入治療及評價. 中國醫師進修雜志, 2007, 30(1): 8-10.
23. Yang J, Yang L, Yu S, et al. Transcatheter versus surgical closure of perimembranous ventricular septal defects in children: A randomized controlled trial. J Am Coll Cardiol, 2014, 63(12): 1159-1168.
24. Santhanam H, Yang L, Chen Z, et al. A meta-analysis of transcatheter device closure of perimembranous ventricular septal defect. Int J Cardiol, 2018, 254: 75-83.
25. Weryński P, Skorek P, Wójcik A, et al. Recent achievements in transcatheter closure of ventricular septal defects: A systematic review of literature and a meta-analysis. Kardiol Pol, 2021, 79(2): 161-169.
26. Bridges ND, Hellenbrand W, Latson L, et al. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation, 1992, 86(6): 1902-1908.
27. Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med, 2012, 366(11): 991-999.
28. Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med, 2013, 368(12): 1092-1100.
29. Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med, 2013, 368(12): 1083-1091.
30. S?ndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med, 2017, 377(11): 1033-1042.
31. Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med, 2017, 377(11): 1011-1021.
32. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med, 2017, 377(11): 1022-1032.
33. 中國心血管健康與疾病報告2019. 心肺血管病雜志, 2020, 39(10): 1157-1162.
34. 國家衛生健康委員會國家結構性心臟病介入質量控制中心,國家心血管病中心結構性心臟病介入質量控制中心,中華醫學會心血管病學分會先心病經皮介入治療指南工作組,等. 常見先天性心臟病經皮介入治療指南(2021版). 中華醫學雜志, 2021, 101(38): 3054-3076.
35. Sharafuddin MJ, Gu X, Titus JL, et al. Experimental evaluation of a new self-expanding patent ductus arteriosus occluder in a canine model. J Vasc Interv Radiol, 1996, 7(6): 877-887.
36. Sharafuddin MJ A, Gu X, Titus JL, et al. Transvenous closure of secundum atrial septal defects: Preliminary results with a new self-expanding nitinol prosthesis in a swine model. Circulation, 1997, 95(8): 2162-2168.
37. Thanopoulos BD, Laskari CV, Tsaousis GS, et al. Closure of atrial septal defects with the Amplatzer occlusion device: Preliminary results. J Am Coll Cardiol, 1998, 31(5): 1110-1116.
38. Thanopoulos BD, Tsaousis GS, Konstadopoulou GN, et al. Transcatheter closure of muscular ventricular septal defects with the amplatzer ventricular septal defect occluder: Initial clinical applications in children. J Am Coll Cardiol, 1999, 33(5): 1395-1399.
39. 戴汝平, 劉延玲, 張戈軍,等. 應用Amplatzer封堵器介入治療房間隔缺損療效評價(附60例報告). 中華心血管病雜志, 2000, 28(2): 87.
40. 蔣世良. 中國先天性心臟病介入治療現狀. 中國實用內科雜志, 2013, 33(4): 259-262.
41. 龐程程, 潘微, 張智偉, 等. 室間隔完整的嚴重肺動脈瓣狹窄或閉鎖胎兒心臟介入治療二例. 中華兒科雜志, 2018, 56(6): 445-450.
42. 張戈軍, 戴汝平, 劉延玲, 等. 房間隔缺損直徑的各種測量方法在介入治療中應用價值. 中國介入心臟病學雜志, 2000, 8(4): 19-22.
43. Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol, 2004, 44(9): 1780-1785.
44. Hellenbrand WE, Fahey JT, McGowan FX, et al. Transesophageal echocardiographic guidance of transcatheter closure of atrial septal defect. Am J Cardiol, 1990, 66(2): 207-213.
45. Kardon RE, Sokoloski MC, Levi DS, et al. Transthoracic echocardiographic guidance of transcatheter atrial septal defect closure. Am J Cardiol, 2004, 94(2): 256-260.
46. 潘湘斌, 逄坤靜, 胡盛壽, 等. 經食管超聲心動圖引導下介入治療房間隔缺損幼兒的有效性和安全性. 中華心血管病雜志, 2013, 41(9): 744-746.
47. 潘湘斌, 逄坤靜, 歐陽文斌, 等. 單純超聲心動圖引導下經皮室間隔缺損封堵術的應用研究. 中國循環雜志, 2015, 30(8): 774-776.
48. 潘湘斌, 歐陽文斌, 李守軍, 等. 單純超聲心動圖引導下行動脈導管未閉封堵術的安全性和有效性. 中華心血管病雜志, 2015, 43(1): 31-33.
49. Yang T, Butera G, Ou-Yang WB, et al. Percutaneous closure of patent foramen ovale under transthoracic echocardiography guidance-midterm results. J Thorac Dis, 2019, 11(6): 2297-2304.
50. 潘湘斌, 胡盛壽, 歐陽文斌, 等. 單純超聲引導下經皮肺動脈瓣球囊成形術的應用研究. 中華小兒外科雜志, 2015, 36(4): 286-288.
51. Kong P, Zhao G, Zhang Z, et al. Novel panna guide wire facilitates percutaneous and nonfluoroscopic procedure for atrial septal defect closure: A randomized controlled trial. Circ Cardiovasc Interv, 2020, 13(9): e009281.
52. Liu Y, Guo GL, Zhang FW, et al. A novel wire is effective for echo-guiding percutaneous atrial septal defect closure: A preclinical study. J Healthc Eng, 2018, 2018: 5784567.
53. Ovaert C, Bonnet D, Malekzadeh-Milani S. Letter by Ovaert et al regarding article, "Novel panna guide wire facilitates percutaneous and nonfluoroscopic procedure for atrial septal defect closure: A randomized controlled trial". Circ Cardiovasc Interv, 2020, 13(11): e010121.
54. Wang C, Zhang F, Ouyang W, et al. Transcatheter closure of patent ductus arteriosus under echocardiography guidance: A randomized controlled noninferiority trial. J Interv Cardiol, 2020, 2020: 4357017.
55. 國家衛生健康委員會國家心外介入質控專家組, 國家心血管病中心醫療質量控制中心心外介入專家組. 單純超聲心動圖引導經皮介入技術中國專家共識. 中國循環雜志, 2018, 33(10): 943-952.
56. Antoniades C, Asselbergs FW, Vardas P. The year in cardiovascular medicine 2020: Digital health and innovation. Eur Heart J, 2021, 42(7): 732-739.
57. Arnaout R, Curran L, Zhao Y, et al. An ensemble of neural networks provides expert-level prenatal detection of complex congenital heart disease. Nat Med, 2021, 27(5): 882-891.
58. Morris SA, Lopez KN. Deep learning for detecting congenital heart disease in the fetus. Nat Med, 2021, 27(5): 764-765.
59. 李林林, 于振坤, 樊紅光, 等. 虛擬現實技術在心血管外科手術教學培訓中的初步應用研究. 中國循環雜志, 2019, 34(3): 289-294.
60. Vukicevic M, Mosadegh B, Min JK, et al. Cardiac 3D printing and its future directions. JACC Cardiovasc Imaging, 2017, 10(2): 171-184.
61. Sigler M, Jux C. Biocompatibility of septal defect closure devices. Heart, 2007, 93(4): 444-449.
62. Huang Y, Kong JF, Venkatraman SS. Biomaterials and design in occlusion devices for cardiac defects: A review. Acta Biomater, 2014, 10(3): 1088-1101.
63. Zahn EM, Wilson N, Cutright W, et al. Development and testing of the Helex septal occluder, a new expanded polytetrafluoroethylene atrial septal defect occlusion system. Circulation, 2001, 104(6): 711-716.
64. Lin C, Liu L, Liu Y, et al. Recent developments in next-generation occlusion devices. Acta Biomater, 2021, 128: 100-119.
65. Kaulitz R, Bertram H, Peuster M, et al. Transcatheter closure of atrial septal defects with the CardioSEAL occluder. Z Kardiol, 2002, 91(2): 169-177.
66. Nugent AW, Britt A, Gauvreau K, et al. Device closure rates of simple atrial septal defects optimized by the STARFlex device. J Am Coll Cardiol, 2006, 48(3): 538-544.
67. Rao PS, Sideris EB, Haddad J, et al. Transcatheter occlusion of patent ductus arteriosus with adjustable buttoned device. Initial clinical experience. Circulation, 1993, 88(3): 1119-1126.
68. Majunke N, Sievert H. ASD/PFO devices: what is in the pipeline? J Interv Cardiol, 2007, 20(6): 517-523.
69. Gruenstein DH, Ebeid M, Radtke W, et al. Transcatheter closure of patent ductus arteriosus using the AMPLATZER? duct occluder Ⅱ (ADO Ⅱ). Catheter Cardiovasc Interv, 2017, 89(6): 1118-1128.
70. Numan M, El Sisi A, Tofeig M, et al. Cribriform amplatzer device closure of fenestrated atrial septal defects: Feasibility and technical aspects. Pediatr Cardiol, 2008, 29(3): 530-535.
71. Koneti NR, Penumatsa RR, Kanchi V, et al. Retrograde transcatheter closure of ventricular septal defects in children using the Amplatzer Duct Occluder Ⅱ. Catheterization and Cardiovascular Interventions, 2011, 77(2): 252-259.
72. Koneti NR, Penumatsa RR, Kanchi V, et al. Retrograde transcatheter closure of ventricular septal defects in children using the Amplatzer Duct Occluder Ⅱ. Catheter Cardiovasc Interv, 2011, 77(2): 252-259.
73. 張戈軍, 徐仲英, 蔣世良, 等. 第二代Amplatzer動脈導管未閉封堵器經股動脈逆行插管行室間隔缺損封堵術療效評價. 臨床薈萃, 2015, 30(6): 601-604.
74. Haddad RN, Daou L, Saliba Z. Device closure of perimembranous ventricular septal defect: Choosing between amplatzer occluders. Front Pediatr, 2019, 7: 300.
75. Holzer R, de Giovanni J, Walsh KP, et al. Transcatheter closure of perimembranous ventricular septal defects using the amplatzer membranous VSD occluder: Immediate and midterm results of an international registry. Catheter Cardiovasc Interv, 2006, 68(4): 620-628.
76. Butera G, Carminati M, Chessa M, et al. Transcatheter closure of perimembranous ventricular septal defects: Early and long-term results. J Am Coll Cardiol, 2007, 50(12): 1189-1195.
77. Zuo J, Xie J, Yi W, et al. Results of transcatheter closure of perimembranous ventricular septal defect. Am J Cardiol, 2010, 106(7): 1034-1037.
78. Yang J, Yang L, Wan Y, et al. Transcatheter device closure of perimembranous ventricular septal defects: Mid-term outcomes. Eur Heart J, 2010, 31(18): 2238-2245.
79. 李俊杰, 張智偉, 錢明陽, 等. 應用偏心型和對稱型封堵器介入治療小兒膜周部室間隔缺損的對比研究. 中國介入心臟病學雜志, 2009, 17(6): 301-304.
80. 秦永文, 趙仙先, 徐榮良, 等. 應用自制封堵器經導管閉合膜部室間隔缺損. 中華心血管病雜志, 2003, 31(1): 31.
81. 袁建華. 淺談介入治療技術的規范化. 介入放射學雜志, 2005, 14(4): 427-429.
82. 秦永文, 趙仙先, 吳弘, 等. 自制非對稱型室間隔缺損封堵器的初步臨床應用. 介入放射學雜志, 2004, 13(2): 101-103.
83. Ou-Yang WB, Li SJ, Wang SZ, et al. Echocardiographic guided closure of perimembranous ventricular septal defects. Ann Thorac Surg, 2015, 100(4): 1398-1402.
84. Yang K, Lyu JH, Hu HB, et al. Efficacy and safety of a parylene-coated occluder for atrial septal defect: A prospective, multi-center, randomized controlled clinical trial. Chin Med J (Engl), 2021, 134(22): 2685-2691.
85. Esteves CA, Solarewicz LA, Cassar R, et al. Occlusion of the perimembranous ventricular septal defect using CERA? devices. Catheter Cardiovasc Interv, 2012, 80(2): 182-187.
86. Lifeng Z, Yan H, Dayun Y, et al. The underlying biological mechanisms of biocompatibility differences between bare and TiN-coated NiTi alloys. Biomed Mater, 2011, 6(2): 025012.
87. Kaya MG, Akpek M, Celebi A, et al. A multicentre, comparative study of Cera septal occluder versus AMPLATZER Septal Occluder in transcatheter closure of secundum atrial septal defects. EuroIntervention, 2014, 10(5): 626-631.
88. Ulmi M, Praz F, Siontis GCM, et al. Propensity-score matched comparison of the cera PFO occluder with the Amplatzer PFO occluder for percutaneous closure of patent foramen ovale without echocardiographic guidance. J Invasive Cardiol, 2017, 29(8): 280-284.
89. Bhattacharjya S, Pillai LS, Doraiswamy V, et al. Prospective concurrent head-to head comparison of three different types of nitinol occluder device for transcatheter closure of secundum atrial septal defects. EuroIntervention, 2019, 15(4): e321-e328.
90. Sievert K, Yu J, Bertog S, et al. Post-market clinical follow-up with the patent foramen ovale closure device IrisFIT (Lifetech) in patients with stroke, transient ischemic attack, or other thromboembolic events. Cardiovasc Revasc Med, 2021, 30: 72-75.
91. Ramot Y, Haim-Zada M, Domb AJ, et al. Biocompatibility and safety of PLA and its copolymers. Adv Drug Deliv Rev, 2016, 107: 153-162.
92. da Silva D, Kaduri M, Poley M, et al. Biocompatibility, biodegradation and excretion of polylactic acid (PLA) in medical implants and theranostic systems. Chem Eng J, 2018, 340: 9-14.
93. In vitro degradation behavior of l-lactide/trimethylene carbonate/glycolide terpolymers and a composite with poly (l-lactide-co-glycolide) fibers-ScienceDirect. [2022-05-07]. https://www.sciencedirect.com/science/article/pii/S0141391014004297.
94. Middleton JC, Tipton AJ. Synthetic biodegradable polymers as orthopedic devices. Biomaterials, 2000, 21(23): 2335-2346.
95. Goonoo N, Jeetah R, Bhaw-Luximon A, et al. Polydioxanone-based bio-materials for tissue engineering and drug/gene delivery applications. Eur J Pharm Biopharm, 2015, 97(Pt B): 371-391.
96. Bartnikowski M, Dargaville T R, Ivanovski S, et al. Degradation mechanisms of polycaprolactone in the context of chemistry, geometry and environment. Progress in Polymer Science, 2019, 96: 1-20.
97. Jux C, Bertram H, Wohlsein P, et al. Interventional atrial septal defect closure using a totally bioresorbable occluder matrix: Development and preclinical evaluation of the BioSTAR device. J Am Coll Cardiol, 2006, 48(1): 161-169.
98. Mullen MJ, Devellian CA, Jux C. BioSTAR bioabsorbable septal repair implant. Expert Rev Med Devices, 2007, 4(6): 781-792.
99. Mullen MJ, Hildick-Smith D, De Giovanni JV, et al. BioSTAR Evaluation STudy (BEST): A prospective, multicenter, phaseⅠclinical trial to evaluate the feasibility, efficacy, and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial-level shunts. Circulation, 2006, 114(18): 1962-1967.
100. Morgan G, Lee KJ, Chaturvedi R, et al. A biodegradable device (BioSTAR) for atrial septal defect closure in children. Catheter Cardiovasc Interv, 2010, 76(2): 241-245.
101. Baspinar O, Kervancioglu M, Kilinc M, et al. Bioabsorbable atrial septal occluder for percutaneous closure of atrial septal defect in children. Tex Heart Inst J, 2012, 39(2): 184-189.
102. Sigler M, S?derberg B, Schmitt B, et al. Carag bioresorbable septal occluder (CBSO): Histopathology of experimental implants. EuroIntervention, 2018, 13(14): 1655-1661.
103. Liu SJ, Peng KM, Hsiao CY, et al. Novel biodegradable polycaprolactone occlusion device combining nanofibrous PLGA/collagen membrane for closure of atrial septal defect (ASD). Ann Biomed Eng, 2011, 39(11): 2759-2766.
104. Zhu YF, Huang XM, Cao J, et al. Animal experimental study of the fully biodegradable atrial septal defect (ASD) occluder. J Biomed Biotechnol, 2012, 2012: 735989.
105. Huang XM, Zhu YF, Cao J, et al. Development and preclinical evaluation of a biodegradable ventricular septal defect occluder. Catheter Cardiovasc Interv, 2013, 81(2): 324-330.
106. Li YF, Xie YM, Chen J, et al. Initial experiences with a novel biodegradable device for percutaneous closure of atrial septal defects: From preclinical study to first-in-human experience. Catheter Cardiovasc Interv, 2020, 95(2): 282-293.
107. Lin C, Lv J, Li Y, et al. 4D-printed biodegradable and remotely controllable shape memory occlusion devices. Adv Funct Mater, 2019, 29(51): 1906569.
108. Lu W, Ouyang W, Wang S, et al. A novel totally biodegradable device for effective atrial septal defect closure: A 2-year study in sheep. J Interv Cardiol, 2018, 31(6): 841-848.
109. 張鳳文, 孫毅, 潘湘斌, 等. 完全可降解封堵器治療膜周部室間隔缺損兩例. 中國胸心血管外科臨床雜志, 2018, 25(7): 636-638.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Current situation and prospect of interventional therapy for congenital heart disease in China

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content